Drug Type Antibody drug conjugate (ADC) |
Synonyms SHR A1912, SHR-A1912, SHRA1912 |
Target |
Mechanism CD79B inhibitors(B-cell antigen receptor complex-associated protein beta chain inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
B-Cell Lymphoma | Phase 2 | CN | 17 Nov 2023 | |
Lymphoma | Phase 2 | CN | - |
Phase 1 | 49 | vhiaavewic(sbbwufmgse) = dfqxasqxxc tdjmpzhxae (tdktvnmjlm, 39.8 - 71.5) | Positive | 24 May 2024 | |||
vhiaavewic(sbbwufmgse) = niypgfkttg tdjmpzhxae (tdktvnmjlm, 39.8 - 71.5) |